Actually management has already gotten on top of this. So due to the DEA we used different suppliers, this resulted in a difference of results between the two groups. When looking at the Aus group the data is presented like x. We conducted a root cause analysis and identified that it was the supply. We then mitigated a supply risk by locking in an agreement as this will be needed for phase 3...
Looking forward to the FDA meeting to help advise us from here.
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-273
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 38.0¢ | 35.0¢ | $4.519M | 12.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 75362 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 326113 | 17 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |